Recent progress of continuous crystallization

Ting Wang,Haijiao Lu,Jingkang Wang,Yan Xiao,Yanan Zhou,Ying Bao,Hongxun Hao 한국공업화학회 2017 Journal of Industrial and Engineering Chemistry Vol.54 No.-

Continuous crystallization has always been a hot topic in industrial crystallization. Many efforts have been made to improve the continuous crystallization, either by designing novel continuous crystallizers or by proposing improved design and operation of conventional continuous crystallizers. Some new models for continuous crystallization processes have also been proposed and tested in recent years. In this work, the development of continuous crystallization in recent years, including novel crystallizers, control strategies, models and some assistive technologies, is summarized. Promising as it is, continuous crystallization is still not as universal as batch crystallization due to the existence of the drawbacks, such as blockage and encrustation. Therefore, further efforts are needed before wider application of continuous crystallization.

Addendum: A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum- sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Ting-Yan Shi,Libing Xiang,Jianqing Zhu,Ji-hong Liu,Ping Zhang,Hua-ying Wang,Yanling Feng,Tao Zhu,Yingli Zhang,Aijun Yu,Wei Jiang,Xipeng Wang,Yaping Zhu,Sufang Wu,Yincheng Teng,Jiejie Zhang,Rong Jiang 대한부인종양학회 2022 Journal of Gynecologic Oncology Vol.33 No.4

A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study

Ting-Yan Shi,Sheng Yin,Jianqing Zhu,Ping Zhang,Jihong Liu,Libing Xiang,Yaping Zhu,Sufang Wu,Xiaojun Chen,Xipeng Wang,Yin-Cheng Teng,Tao Zhu,Aijun Yu,Yingli Zhang,Yanling Feng,He Huang,Wei Bao,Yanli Li 대한부인종양학회 2020 Journal of Gynecologic Oncology Vol.31 No.3

Background: In China, secondary cytoreductive surgery (SCR) has been widely used in ovarian cancer (OC) over the past two decades. Although Gynecologic Oncology Group-0213 trial did not show its overall survival benefit in first relapsed patients, the questions on patient selection and effect of subsequent targeting therapy are still open. The preliminary data from our pre-SOC1 phase II study showed that selected patients with second relapse who never received SCR at recurrence may still benefit from surgery. Moreover, poly(ADP-ribose) polymerase inhibitors (PARPi) maintenance now has been a standard care for platinum sensitive relapsed OC. To our knowledge, no published or ongoing trial is trying to answer the question if patient can benefit from a potentially complete resection combined with PARPi maintenance in OC patients with secondary recurrence. Methods: SOC-3 is a multi-center, open, randomized, controlled, phase II trial of SCR followed by chemotherapy and niraparib maintenance vs chemotherapy and niraparib maintenance in patients with platinum-sensitive second relapsed OC who never received SCR at recurrence. To guarantee surgical quality, if the sites had no experience of participating in any OC-related surgical trials, the number of recurrent lesions evaluated by central-reviewed positron emission tomography–computed tomography image shouldn't be more than 3. Eligible patients are randomly assigned in a 1:1 ratio to receive either SCR followed by 6 cycles of platinum-based chemotherapy and niraparib maintenance or 6 cycles of platinum-based chemotherapy and niraparib maintenance alone. Patients who undergo at least 4 cycles of chemotherapy and must be, in the opinion of the investigator, without disease progression, will be assigned niraparib maintenance. Major inclusion criteria are secondary relapsed OC with a platinum-free interval of no less than 6 months and a possibly complete resection. Major exclusion criteria are borderline tumors and non-epithelial ovarian malignancies, received debulking surgery at recurrence and impossible to complete resection. The sample size is 96 patients. Primary endpoint is 12-month non-progression rate. Trial Registration: ClinicalTrials.gov Identifier: NCT03983226

Efficacy and Safety of Sorafenib for Advanced Non-Small Cell Lung Cancer: a Meta-analysis of Randomized Controlled Trials

Wang, Wei-Lan,Tang, Zhi-Hui,Xie, Ting-Ting,Xiao, Bing-Kun,Zhang, Xin-Yu,Guo, Dai-Hong,Wang, Dong-Xiao,Pei, Fei,Si, Hai-Yan,Zhu, Man Asian Pacific Journal of Cancer Prevention 2014 Asian Pacific journal of cancer prevention Vol.15 No.14

Background: Many clinical trials have been conducted to evaluate sorafenib for the treatment of advanced NSCLC, but the results for efficacy have been inconsistent. The aim of this study was to evaluate the efficacy and safety of sorafenib in patients with advanced NSCLC in more detail by meta-analysis. Methods: This meta-analysis of randomized controlled trials (RCTs) was performed after searching PubMed, EMBASE, ASCO Abstracts, ESMO Abstracts, and the proceedings of major conferences for relevant clinical trials. Two reviewers independently assessed the quality of the trials. Outcomes analysis were disease control rate (DCR), progression- free survival (PFS), overall survival (OS) with 95% confidence intervals (CI) and major toxicity. Subgroup analysis was conducted according to sorafenib monotherapy, in combination with chemotherapy or EGFR-TKI to investigate the preferred therapy strategy. Results: Results reported from 6 RCTs involving 2, 748 patients were included in the analysis. Compared to sorafenib-free group, SBT was not associated with higher DCR (RR 1.31 (0.96- 1.79), p=0.09), PFS (HR 0.82 (0.66-1.02), p=0.07) and OS (HR 1.01 (0.92-1.12), p=0.77). In terms of subgroup results, sorafenib monotherapy was associated with significant superior DCR and longer PFS, but failed to show advantage with regard to OS. Grade 3 or greater sorafenib-related adverse events included fatigue, hypertension, diarrhea, oral mucositis, rash and HFSR. Conclusions: SBT was revealed to yield no improvement in DCR, PFS and OS. However, sorafenib as monotherapy showed some activity in NSCLC. Further evaluation may be considered in subsets of patients who may benefit from this treatment. Sorafenib combined inhibition therapy should be limited unless the choice of platinum-doublet regimen, administration sequence or identification of predictive biomarkers are considered to receive better anti-tumor activity and prevention of resistance mechanisms.

The Impact of Teacher-Student Interaction on Learning Performance - Focusing on the Mediating Effect of Learning Engagement -

왕정정 ( Wang Ting-ting ),이염남 ( Li Yan-nan ) 국제뇌교육종합대학원 인성교육연구원 2023 인성교육연구 Vol.8 No.2

본 연구는 교사-학생 상호작용이 학습 성과에 미치는 영향을 탐구하며, 학습 몰입의 매개 역할이라는 점에 집중하였다. 연구방법은 중국과 한국의 312명 대학(원)생을 대상으로 한 설문 조사를 포함하며, 연구목적을 검증하기 위해 SPSS 23.0을 사용하여 분석하였다. 연구결과를 살펴보면 교사-학생 상호작용이 학습 성과와 학습 참여에 긍정적으로 영향을 미치며, 학습 참여도 학습 성과에 긍정적인 영향을 미친다는 것을 확인하였다. 또한, 본 연구는 학습 참여가 교사-학생 상호작용의 학습 성과에 대한 영향을 매개한다는 결과를 검증하였다는 점이다. 교육 과정의 이러한 중요한 요소를 연결함으로써, 본 연구는 다양한 교육 환경에서 교육자가 교육과 학습의 질 효과를 향상시키려는 데 유용한 통찰력을 제공할 것이다. 또한 본 연구는 학습자 참여와 참여 유도에 대한 교육자에게 중요한 지침을 제공하며, 교육 정책 결정자에게는 교육 환경을 개선하여 교사-학생 상호작용과 학습 참여를 촉진하는 방법에 대한 의견을 제시함으로써 교육의 품질 향상과 학생의 학업 성취도 향상에 기여할 것이라고 생각한다. This study investigates the impact of teacher-student interaction on learning performance, with a particular emphasis on the mediating role of learning engagement. The research methodology involved a survey of 312 students from both China and Korea, and to verify the research objectives, the data were analyzed using SPSS 23.0. The results of the study confirm that teacher-student interaction positively influences both learning performance and learning engagement, while learning engagement also has a positive impact on learning performance. Furthermore, the study validates that learning engagement mediates the effect of teacher-student interaction on learning performance. Additionally, this research offers essential guidance for educators looking to foster student engagement and participation, and it provides recommendations for education policymakers on ways to improve the educational environment, thereby promoting teacher-student interaction and learning engagement, ultimately contributing to the enhancement of education quality and students' academic achievements.

miR-638 is a new biomarker for outcome prediction of non-small cell lung cancer patients receiving chemotherapy

Fang Wang,Jian-fang Lou,Yan Cao,Xin-hui Shi,Peng Wang,Jian Xu,Er-fu Xie,Ting Xu,Rui-hong Sun,Jianyu Rao,Pu-wen Huang,Shi-yang Pan,Hong Wang 생화학분자생물학회 2015 Experimental and molecular medicine Vol.47 No.-

MicroRNAs (miRNAs), a class of small non-coding RNAs, mediate gene expression by either cleaving target mRNAs or inhibiting their translation. They have key roles in the tumorigenesis of several cancers, including non-small cell lung cancer (NSCLC). The aim of this study was to investigate the clinical significance of miR-638 in the evaluation of NSCLC patient prognosis in response to chemotherapy. First, we detected miR-638 expression levels in vitro in the culture supernatants of the NSCLC cell line SPC-A1 treated with cisplatin, as well as the apoptosis rates of SPC-A1. Second, serum miR-638 expression levels were detected in vivo by using nude mice xenograft models bearing SPC-A1 with and without cisplatin treatment. In the clinic, the serum miR-638 levels of 200 cases of NSCLC patients before and after chemotherapy were determined by quantitative real-time PCR, and the associations of clinicopathological features with miR-638 expression patterns after chemotherapy were analyzed. Our data helped in demonstrating that cisplatin induced apoptosis of the SPC-A1 cells in a dose- and time-dependent manner accompanied by increased miR-638 expression levels in the culture supernatants. In vivo data further revealed that cisplatin induced miR-638 upregulation in the serum derived from mice xenograft models, and in NSCLC patient sera, miR-638 expression patterns after chemotherapy significantly correlated with lymph node metastasis. Moreover, survival analyses revealed that patients who had increased miR-638 levels after chemotherapy showed significantly longer survival time than those who had decreased miR-638 levels. Our findings suggest that serum miR-638 levels are associated with the survival of NSCLC patients and may be considered a potential independent predictor for NSCLC prognosis.

Shear and tensile behaviors of headed stud connectors in double skin composite shear wall

Jia-Bao Yan,Zhe Wang,Tao Wang,Xiao-Ting Wang 국제구조공학회 2018 Steel and Composite Structures, An International J Vol.26 No.6

This paper studies shear and tensile behaviors of headed stud connectors in double skin composite (DSC) structure. Firstly, 11 push-out tests and 11 tensile tests were performed to investigate the ultimate shear and tensile behaviors of headed stud in DSC shear wall, respectively. The main parameters investigated in this test program were height and layout of headed stud connectors. The test results reported the representative failure modes of headed studs in DSC structures subjected to shear and tension. The shear-slip and tension-elongation behaviors of headed studs in DSC structures were also reported. Influences of different parameters on these shear-slip and tension-elongation behaviors of headed studs were discussed and analyzed. Analytical models were also developed to predict the ultimate shear and tensile resistances of headed stud connectors in DSC shear walls. The developed analytical model incorporated the influence of the dense layout of headed studs in DSC shear walls. The validations of analytical predictions against 22 test results confirmed the accuracy of developed analytical models.

Development and Validation of Nomograms to Provide Individualized Predictions of Sur-vival Benefits from Surgery in Patients with Intermediate/Advanced Hepatocel-lular Carcinoma

( Wen-tao Yan ),( Jia-he Wang ),( Ming-da Wang ),( Zheng Wang ),( Bing Quan ),( Ya-hao Zhou ),( Wei-min Gu ),( Hong Wang ),( Ting-hao Chen ),( Tian Yang ) 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1

Aims: According to the BCLC treatment guidelines, surgery does not be recommended for intermediate/advanced hepatocellular carcinoma (HCC). In real world, however, liver resections are often performed in patients with intermediate/ advanced but resectable HCC, especially in the East. Methods: We retrospectively evaluated multicentric data of 1,325 patients newly diagnosed with intermediate/advanced HCC who underwent curative resection. We randomly divided the subjects into development (n = 875) and validation (n = 450) samples. Multivariate Cox proportional hazards models were developed and separately validated on the basis of patients’ clinicopathological variables assessed for associations with 1-year recurrence and 3-year mortality. The discriminatory accuracy of these models was compared with conventional tools by analyzing receiver operating characteristic (ROC) curves. Results: He statistical nomograms built based on performance status, Child-Pugh grade, portal hypertension, preoperative alpha-fetoprotein level, tumor rupture, largest tumor diameter, tumor number, macrovascular and microvascular invasion, and satellites had good calibration and discriminatory abilities, with c-indices of 0.70 (1-year recurrence) and 0.68 (3-year survival), respectively. These models showed satisfactory goodness-of-fit and discrimination abilities in the validation cohort (c-index, 0.68 for 1-year recurrence and 0.69 for 3-year survival). The areas under the ROC curve using these nomograms exceeded those of traditional staging systems, indicating superior discriminatory capability (c-indices, 0.60-0.63 and 0.56-0.62, respectively). Conclusions: Our proposed online nomograms, which present graphically postoperative prognostic models for recurrence and survival in patients with intermediate/advanced but resectable HCC, offer valuable guidance to surgeons and hepatologists for individually predicting survival benefits from surgery and planning recurrence surveillance and adjuvant therapy.

Prognostic Significance of Interactions Between ER Alpha and ER Beta and Lymph Node Status in Breast Cancer Cases

Han, Shu-Jing,Guo, Qing-Qing,Wang, Ting,Wang, You-Xin,Zhang, Yu-Xiang,Liu, Fen,Luo, Yan-Xia,Zhang, Jie,Wang, You-Li,Yan, Yu-Xiang,Peng, Xiao-Xia,Ling, Rui,He, Yan Asian Pacific Journal of Cancer Prevention 2013 Asian Pacific journal of cancer prevention Vol.14 No.10

Objective: Both estrogen receptors, ER alpha ($ER{\alpha}$) and ER beta ($ER{\beta}$), are expressed in 50-70% of breast cancer cases. The role of $ER{\alpha}$ as a prognostic marker in breast cancer has been well established as its expression is negative correlated with tumor size and lymph node metastasis. $ER{\beta}$ is also a favorable prognostic predictor although this is less well documented than for $ER{\alpha}$. Materials and Methods: To explore whether ERs independently or together might influence clinical outcome in breast cancer, the correlation between the ERs with the clinicopathological features was analyzed in 84 patients. Results: $ER{\alpha}$ expression negatively correlated with tumor stage (r=-0.246, p=0.028) and tended to be negatively correlated with lymph node status (r=-0.156, p=0.168) and tumor size (r=-0.246, p=0.099). Also, $ER{\beta}$ was negatively correlated with nodal status (r=-0.243, p=0.028), as was coexpression of $ER{\alpha}$ and $ER{\beta}$ (p=0.043, OR=0.194, 95% CI= 0.040-0.953). Conclusion: Coexpression of ERs might serve as an indicator of good prognosis in breast cancer patients.

Effects of a novel marine natural product: pyrano indolone alkaloid fibrinolytic compound on thrombolysis and hemorrhagic activities in vitro and in vivo

Ting Yan,Wen-Hui Wu,Tongwei Su,Jiajie Chen,Quangang Zhu,Chaoyan Zhang,Xiaoyu Wang,Bin Bao 대한약학회 2015 Archives of Pharmacal Research Vol.38 No.8

Fungi fibrinolytic compound 1 (FGFC1) is a novel marine natural product as a low-weight fibrinolytic pyranoindole molecule, whose thrombolytic effects were evaluated on FITC-fibrin (Fluorescein isothiocyanate, FITC) degradation methods in vitro and on acute pulmonary thromboembolism animal model in vivo. We determined the FGFC1 induced thrombolysis that stems from its fibrin(ogen)olytic activities as measured by fibrin(ogen) degradation products (FDPs) experiment, acute pulmonary thromboembolism animal model experiment, and euglobulin lysis assay. In vitro, measurement of FITCfibrin degradation revealed that fibrin hydrolysis occurred in a concentration-dependent manner of FGFC1 from 5 to 25 l mol/L. In vivo test of a classical acute pulmonary thromboembolism model in rat showed that when the injected dose was 5 mg/kg or above, FGFC1 was effectivein dissolution of extrinsic FITC-fibrin induced blood clots. Euglobulin lysis time (ELT) in FGFC1-treated rats was shortened 30 s compared with rats in the positive control group, which were injected with clopidogrel sulfate and single-chain urokinase-type plasminogen activator. As compared to the control, FGFC1 (5–25 mg/kg) did not significantly alter the formation of fibrinogen and FDPs in vivo. Our research indicates that FGFC1 presents pharmacodynamic action in both the thrombolysis and the hemolytic procedure, which can be characterized by fibrinogenolysis in blood and FDPs in plasma. In vivo, increasing fibrinolytic doses of FGFC1 from 5 to 25 mg/kg did not induce fibrinogenolysis when compared with control group, this result corresponds to that FGFC1 did not induce the increasing of FDPs (compared with the salinetreated control). It indicates that the FGFC1 may act as a novel thrombolytic agent and represent an effective approach to the treatment of thrombus without significant risk of hemorrhagic activity.